Clinical trials: DED
Dry Eye
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
- Trial name
- NCT04747977
- Testing
- OTX-DED
- Where
- 15 sites in United States
- Volunteers
- 172 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT04036292
- Testing
- OC-01 (varenicline) nasal spray
- Where
- 22 sites in United States
- Volunteers
- 758 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Disease
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
- Trial name
- NCT03292809
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 9 sites in United States
- Volunteers
- 328 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease (DED)
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland…
- Trial name
- NCT04139798
- Testing
- NOV03
- Where
- 29 sites in United States
- Volunteers
- 599 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline…
- Trial name
- NCT03785340
- Testing
- Brimonidine Tartrate
- Where
- 16 sites in United States
- Volunteers
- 252 people
- Sponsor
- Ocugen
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH